Ab Initio Biotherapeutics
South San Francisco
About Ab Initio Biotherapeutics
Ab Initio Biotherapeutics operates as an antigen-discovery company. Its proprietary antigen discovery platform allows for targeting multi-transmembrane proteins such as GPCRs and facilitates antibody generation relevant to a wide array of therapeutic indications including neurological, cardiovascular, endocrine and gastrointestinal disorders.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Website: aibio.com
Social Profiles
Canonical: https://fsome.com/organization/ab-initio-biotherapeutics-495768 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.